Incyte is a global biopharmaceutical company, founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. The company has grown to employ over 1400 people and has operations in the U.S., Europe, and Japan. Incyte focuses on the discovery and development of small-molecule drugs.
The company has a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. They are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
Clinical trials are testing the viability of Incyte drugs for the treatment of coronavirus. As of February 2020, Camrelizumab (humanized monoclonal antibody targeting PD-1) and thymosin are being used in two ongoing clinical trials.
Barry P. Flannelly
Executive Vice President, General Manager, US
Executive Vice President and Chief Financial Officer
Executive Vice President and Chief Scientific Officer
Chairman, President and Chief Executive Officer
Jonathan E. Dickinson
Executive Vice President and General Manager, Europe
Lothar H. Finke
Head of Clinical Development and General Manager, Japan
Maria E. Pasquale
Executive Vice President, General Counsel
Executive Vice President and Head of Global Technical Operations
Paula J. Swain
Executive Vice President, Human Resources
Steven H. Stein
Executive Vice President, Chief Medical Officer
Executive Vice President, Global Strategy and Corporate Development
Executive Vice President, Discovery Chemistry
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.